Ongoing Phase III clinical trials explore the use of alpelisib with other agents, including its combination with trastuzumab and pertuzumab for HER2+ breast cancer with PI3KCA mutations (EPIK-B2) [115] and with nab-paclitaxel for triple-negative breast cancer (EPIK-B3) [116]. The gene discussed is ERBB2; the disease is breast cancer.